1. A class action lawsuit has been filed against LifeMD, Inc. (LFMD). 2. Allegations include misleading investors about company performance and business prospects. 3. LFMD's stock fell by 44.8% following revised revenue guidance. 4. Class period for affected investors is from May 7 to August 5, 2025. 5. Shareholders can participate in a lead plaintiff role until October 27, 2025.
The class action lawsuit signifies serious investor mistrust, reminiscent of past stock declines due to legal issues.
The allegations could significantly impair investor trust and stock value, as seen in similar past events.
The immediate effect of the lawsuit and stock drop is likely to persist, impacting investor sentiment.
SAN DIEGO, Aug. 27, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired LifeMD, Inc. (NASDAQ:LFMD) securities between May 7, 2025 and August 5, 2025. LifeMD is a leading provider of virtual primary care.
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
The Allegations: Robbins LLP is Investigating Allegations that LifeMD, Inc. (LFMD) Misled Investors Regarding its Business Prospects
According to the complaint, during the class period, defendants failed to disclose that: (1) defendants materially overstated LifeMD's competitive position; (2) defendants were reckless in raising LifeMD's 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD's RexMD segment, as well as for customer acquisition costs related to the sale of drugs designed to treat obesity, including Wegovy and Zepbound; and (3) as a result, defendants' statements about LifeMD's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
On August 5, 2025, LifeMD issued a press release regarding its second quarter 2025 results, noting that due to "some temporary challenges facing our Rex MD business," which were "largely resolved," the Company was "revising our full year 2025 guidance for revenue and adjusted EBITDA to reflect the full-year impact of these issues, while still anticipating strong year-over-year growth in both metrics." On this news, the price of LifeMD common stock fell $5.31 per share, or 44.8%, to close at $6.53 on August 6, 2025.
What Now: You may be eligible to participate in the class action against LifeMD, Inc. Shareholders who wish to serve as lead plaintiff for the class must file their papers with the court by October 27, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.
To be notified if a class action against LifeMD, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-robbins-llp-informs-investors-of-the-lifemd-inc-class-action-lawsuit-302540625.html
SOURCE Robbins LLP